Shield Therapeutics H1 revenue reaches $30.4 million as prescriptions grow 21%

Shield Therapeutics has reported a profitable first half of 2026, supported by rising ACCRUFeR prescriptions and a $7.9 million development milestone from its Chinese partner.

However, the detail is more mixed than the headline numbers initially suggest. Second-quarter revenue fell against the prior year, while changes to Medicaid prescription approval requirements in New York weighed on ACCRUFeR's average net price.

The central investor question is whether stronger commercial prescriptions can translate into sustainable revenue growth as Shield works towards profitability across the full 2026 financial year.

Shield Therapeutics' H1 2026 figures

Metric	Latest figure	Comparison
H1 group revenue	$30.4 million	$21.5 million in H1 2025
Q2 group net revenue	$11.9 million	$14.3 million in Q2 2025
Q2 ACCRUFeR revenue	$10.3 million	$12.8 million in Q2 2025
Q2 prescriptions	Approximately 49,000	Approximately 47,000 in Q2 2025
H1 prescriptions	Approximately 102,000	Approximately 84,000 in H1 2025
Q2 average net price	$208	$231 in Q2 2025
Cash at 30 June 2026	$8.3 million	$12.4 million at 31 March 2026

H1 revenue increased by approximately 41% year on year, although the comparison benefited from the $7.9 million development milestone earned from ASK in China and higher partner royalties.

That milestone is valuable, but it is not the same as recurring product revenue. Investors therefore need to look beyond the group total and examine ACCRUFeR's underlying US commercial performance.

You can read the figures in the original company announcement.

Prescription growth is the main operational positive

ACCRUFeR is Shield's oral treatment for iron deficiency, with or without anaemia. The product generated Q2 net revenue of $10.3 million, down from $12.8 million a year earlier.

Despite that revenue decline, the number of prescriptions dispensed continued to rise. Q2 prescriptions increased to approximately 49,000 from approximately 47,000, while the H1 total grew 21% to approximately 102,000.

This is encouraging because it indicates that patient and prescriber demand continued to expand. The difficulty was monetising that demand at the same rate as before.

The average net price fell to $208 in Q2 from $231 in the comparable period. Shield attributed the pressure to changes in prior authorisation requirements within New York's Medicaid programme. Prior authorisation means an insurer or public healthcare programme must approve a prescription before agreeing to cover it.

Management responded by shifting its attention towards commercial business outside Medicaid. Shield said this commercial segment grew 27% in H1 compared with the prior year, with June delivering 6% month-on-month growth.

The company had previously used a similar Medicaid-to-commercial pivot in Texas. Management's confidence is therefore based on its own operating experience, although New York's eventual outcome has yet to be demonstrated.

Why the Q2 revenue decline matters

The weaker Q2 comparison prevents this from being a straightforward growth update.

Group net revenue declined from $14.3 million to $11.9 million, while ACCRUFeR revenue dropped from $12.8 million to $10.3 million. Prescriptions rose, but lower pricing more than offset the additional volume.

That relationship between prescription volume and net price is now one of the most important metrics to monitor. Continued prescription growth would be less meaningful financially if access restrictions, payer mix or discounts keep revenue per prescription under pressure.

On the positive side, Shield's commercial segment represents around two-thirds of total revenue and appears to be growing. A successful move towards commercially insured patients could improve the revenue mix over time.

This update follows Shield's strong Q1 2026 performance, when the company reported positive earnings before interest and tax. The Q2 figures show why execution still matters even as the broader profitability story develops.

Profitability remains on track, but cash declined

Shield said it remained profitable during H1 and continues to target profitability in 2026.

That is a meaningful step for a commercial-stage pharmaceutical business, but the quality and repeatability of those profits deserve attention. H1 benefited from the $7.9 million Chinese development milestone, and the company did not disclose an H1 profit figure in this trading update.

Cash and cash equivalents stood at $8.3 million on 30 June, down from $12.4 million at the end of March. Shield said the movement was primarily driven by working capital and cost management, but did not provide a full cash-flow breakdown.

The reduction does not automatically undermine the profitability target because accounting profit and cash generation are different measures. Still, investors will want evidence that recurring commercial operations can support the business without relying heavily on milestone timing.

Shield had previously reported positive cash flow in Q4 2025 and forecast an operating profit for 2026. The next results should help establish whether the latest cash decline was mainly a timing issue or a more persistent feature of growth.

New sales channel and wider regulatory progress

Shield signed its first group purchasing organisation contract, creating an opportunity to market and sell ACCRUFeR to more than 400 clinics. A group purchasing organisation negotiates purchasing arrangements for a network of healthcare providers.

No revenue expectation or launch timetable was disclosed, so the contract should currently be viewed as an expansion of market access rather than a quantified earnings driver.

There was also progress beyond the core US adult market:

• MEDLEAP Pharma enrolled the first patient in a Japanese Phase II trial of ferric maltol for pulmonary arterial hypertension.
• European and UK approvals were received to extend treatment to paediatric patients aged 12 and over.
• The US indication was extended to paediatric patients aged 10 and over from 1 April 2026.
• Discussions took place with potential partners regarding assets that could be licensed for US commercialisation.

These developments broaden ACCRUFeR's potential reach and could support longer-term growth. However, Shield did not disclose their expected financial contribution.

Leadership change as Michael Jensen becomes CFO

Michael Jensen will join Shield as chief financial officer on 1 September 2026.

He brings more than 20 years of financial leadership experience across biopharmaceuticals, medical devices and healthcare. His previous positions include CFO roles at StimLabs, Synlogic and Intrinsic Therapeutics, alongside senior finance roles at Novo Nordisk, Novartis and Siemens Healthcare Diagnostics.

The appointment comes at an important stage. Shield is trying to turn prescription growth into sustained profitability while managing pricing, working capital and commercial expansion. Jensen's immediate priorities were not disclosed, but financial discipline and operational execution are likely to remain prominent investor considerations.

What investors should watch next

Shield's H1 update contains genuine progress. Revenue increased to $30.4 million, prescriptions rose 21%, the commercial segment grew, and management maintained its 2026 profitability objective.

The counterweight is that Q2 revenue declined, average net pricing weakened and cash fell by $4.1 million during the quarter. H1 profitability also benefited from a sizeable development milestone.

The most useful indicators in future updates will be ACCRUFeR's average net price, commercial prescription growth, quarterly cash movement and profitability excluding one-off milestones. If Shield can stabilise pricing while continuing to grow prescriptions, the underlying investment case would become clearer. If pricing pressure persists, higher prescription volumes may take longer to produce the financial returns investors expect.